MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not

British Journal of Cancer

Volumn 98, Issue 11, 2008, Pages 1820-1823

  Langers, A M J ^a   Sier, C F M ^a   Hawinkels, L J A C ^a   Kubben, F J G M ^a   Van Duijn, W ^a   Van Der Reijden, J J ^a   Lamers, C B H W ^a   Hommes, D W ^a   Verspaget, H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Metalloproteinase; Prognosis; SNP; Survival

Indexed keywords

GELATINASE A; GELATINASE B;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

COLORECTAL NEOPLASMS; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 44349097424     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604380     Document Type: Article

References (27)

1. Cauwe B, Van den Steen PE, Opdenakker G (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42: 113-185
2. de Vicente JC, Lequerica-Fernandez P, Santamaria J, Fresno MF (2007) Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 36: 415-424
3. Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, Van Duijn W, van den Berg M, Van Hogezand RA, Lamers CB, Verspaget HW (2005) Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 37: 584-592
4. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O, Laato M (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121: 714-723
5. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, Van Duijn W, Zuidwijk K, Van der Reijden JJ, Hanemaaijer R, Griffioen G, Lamers CB, Verspaget HW (2007) Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43: 1869-1876
6. Kubben FJ, Sier CF, Meijer MJ, van den BM, Van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW (2006a) Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 95: 744-751
7. Kubben FJ, Sier CF, Van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB, Verspaget HW (2006b) Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 94: 1035-1040
8. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
9. Meijer MJ, Mieremet-Ooms MA, Van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, Van Hogezand RA, Lamers CB, Verspaget HW (2006) Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 13: 200-210
10. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
11. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Danø K (1996) 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57-62
12. Overall CM, Blobel CP (2007) In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 8: 245-257
13. Owen JL, Iragavarapu-Charyulu V, Lopez DM (2004) T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis 20: 145-153
14. Patterson BC, Sang QA (1997) Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272: 28823-28825
15. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10: 7621-7628
16. Pozzi A, LeVine WF, Gardner HA (2002) Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21: 272-281
17. Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene - role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276: 7549-7558
18. Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K (2003) Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103: 647-651
19. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW (1996) Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417
20. Sier CF, Verspaget HW, Griffioen G, Verheijen JH, Quax PH, Dooijewaard G, De Bruin PA, Lamers CB (1991) Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 101: 1522-1528
21. Sillanpaa S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma VM (2007) Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 104: 296-303
22. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274
23. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H (1997) Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 88: 72-81
24. Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87: 287-297
25. Xu E, Lai M, Lv B, Xing X, Huang Q, Xia X (2004) A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 324: 999-1003
26. Xu E, Xia X, Lu B, Xing X, Huang Q, Ma Y, Wang W, Lai M (2007) Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog 46: 924-929
27. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794